Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Table 3 Multiple stepwise regression analysis of influencing factors, including age, anthropometric parameters, immunological and virological indicators on lipid and uric metabolism parameters (n = 61)

Independent variable		B	Std. error	Beta	t	p
TC (mmol/L)	Constant	3.224	0.681	–	4.733	<0.0001
	Body weight (kg)	0.053	0.017	0.781	3.161	0.002
	Age (year)	0.031	0.007	0.369	4.249	<0.0001
	Body nonfat weight (kg)	− 0.064	0.028	− 0.578	− 2.319	0.023
	Follow-up weeks	0.006	0.002	0.269	3.308	0.003
TG (mmol/L)	Constant	18.767	5.130	–	3.658	0.001
	Body weight (kg)	0.902	0.192	3.564	4.696	<0.0001
	Body nonfat weight (kg)	− 0.768	0.157	− 1.883	− 4.889	<0.0001
	Body mass index (kg/m²)	− 1.684	0.477	− 1.798	− 3.528	0.001
	Age (year)	0.095	0.042	0.293	2.249	0.031
HDL-c (mmol/L)	Constant	1.153	0.169	–	6.805	<0.0001
	Body mass index (kg/m²)	0.070	0.015	0.791	4.699	<0.0001
	CD3+CD4+ count (cells/µL)	0.001	0.000	0.423	4.930	<0.0001
	Body weight (kg)	− 0.028	0.004	− 1.145	− 6.174	<0.0001
LDL-c (mmol/L)	Constant	1.056	0.374	–	2.827	0.006
	Body mass index (kg/m²)	0.073	0.017	0.396	4.222	<0.0001
	Follow-up weeks	0.003	0.002	0.173	1.847	0.068
UA (µmol/L)	Constant	323.772	15.315	–	21.141	<0.0001
UA (µmol/L)	Virus load (IU/mL)	0.000	0.000	0.313	2.032	0.049

TG, triglyceride; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; UA, uric acid

ISSN: 1758-5996